Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Anterior Uveitis Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Anterior Uveitis Overview | 7 | 1 |
| Anterior Uveitis Therapeutics under Development by Companies | 8 | 1 |
| Anterior Uveitis Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Anterior Uveitis Products under Development by Companies | 12 | 1 |
| Anterior Uveitis Companies Involved in Therapeutics Development | 13 | 5 |
| Aciont Inc. | 13 | 1 |
| Aldeyra Therapeutics, Inc. | 14 | 1 |
| EyeGate Pharmaceuticals, Inc. | 15 | 1 |
| KPI Therapeutics, Inc. | 16 | 1 |
| Neuroptis Biotech | 17 | 1 |
| Anterior Uveitis Therapeutics Assessment | 18 | 9 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Target | 19 | 2 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 17 |
| dalazatide Drug Profile | 27 | 5 |
| dexamethasone acetate Drug Profile | 32 | 4 |
| dexamethasone sodium phosphate Drug Profile | 36 | 2 |
| LME-636 Drug Profile | 38 | 1 |
| NOP-3 Drug Profile | 39 | 1 |
| NS-2 Drug Profile | 40 | 4 |
| Anterior Uveitis Dormant Projects | 44 | 1 |
| Anterior Uveitis Discontinued Products | 45 | 1 |
| Anterior Uveitis Product Development Milestones | 46 | 8 |
| Featured News &Press Releases | 46 | 1 |
| May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis | 46 | 1 |
| Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437 | 47 | 1 |
| Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis | 47 | 1 |
| May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis | 48 | 1 |
| Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial | 49 | 1 |
| Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial | 49 | 1 |
| Mar 19, 2015: Kineta s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases | 49 | 1 |
| Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program | 50 | 1 |
| Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences | 50 | 1 |
| Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis | 51 | 1 |
| Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis | 51 | 1 |
| Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437 | 52 | 1 |
| Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |